Biotechniques

http://www.SinoBiological.com

Sino Biological Inc

Biological Specialist for Protein and Antibody

Production & Quality Reagents

Attractive Cost Saving for Products & Services

Introduction

Sino Biological Inc was founded in January 2007 in Beijing, P.R. China by biotech pioneer and worldwide expert, MIT institute professor, Dr. Daniel I.C. Wang and his former student, Dr. Liangzhi Xie. Sino Biological Inc is quickly becoming the leading global biological solution specialist, offering a comprehensive set of value-added and cost-effective premium quality solutions (services and reagents) to accelerate life science research and biological product development worldwide. Its customers include top-10 global pharmaceutical and biotech companies, small biotech companies, and academic institutions worldwide.

Management Team

Dr. Daniel I.C. Wang

Chairman of the Scientific Advisory Board, Institute Professor at MIT, Member of National Academy of Engineering, American Academy of Arts and Sciences, and Academia Sinica.

Dr. Liangzhi Xie

President and CEO, MIT Ph.D., Former Research Fellow from Merck & Company.

Dr. Ningning Ma

Vice President, Ohio State University Ph.D., Former Sr. Principle Scientist and Group Leader from Pfizer, Inc.

Business Focus

• One-Stop Biology Services for protein and antibody discovery, research, development, production, and commercialization
• Affordable Premium Quality Reagents: Proteins, Antibodies, Kits, Transfection Reagents, Enzymes, Resins, and other Research Tools

Missions:

• To become the preferred centralized protein and antibody production lab serving the entire life science community worldwide
• To assist our customers to develop better and more life-saving therapeutic products, vaccines, and diagnostic methods at faster speed and cheaper cost
• To allow our customers to focus on what they do best and make their job easier and more efficient while saving cost

Track Records

• >400 recombinant monoclonal antibody production projects (10mg to 30 gram) for our customers worldwide in the past two years, More than 100 of these were intended for pre-clinical in vivo studies
• >600 recombinant proteins produced at bulk quantities in two years
• Produced H1N1 hemagglutinin protein from the 2009 swine influenza within 30-days of public release of the virus gene sequenc e
• First in developing high affinity and highly specific monoclonal antibodies to the 2009 H1N1 virus (no cross-reactivity to seasonal flu H1N1 viruses). Our ELISA kit can detect pg/well H1N1 HA protein.

Capabilities and Capacities

• Extensive expertise includin g molecular biology, protein and antibody production, rabbit and mouse monoclonal antibody generation, biological QC testing, biological formulation development and stability testing, and diagnostic assay development.
• >50 stirred tank bioreactors for cell culture and fermentation and purification systems.
• >30,000 L cell culture per year.
• >1000 recombinant monoclonal antibody production by transient transfection per year.
• >500 recombinant pr otein bulk production per year.
• >1000 rabbit and mouse monoclonal antibody development programs per year.
• No lead time for customer projects.

Advanced Technology Platforms

• HEK293 Transient Transfection Platform for Recombinant Protein & Antibody Production
• CHO Transient Transfecti on Platform for Recombinant Protein & Antibody Production
• CHO Stable Cell Line Platform for Recombinant Protein & Antibody Production
• Bacterial (E. Coli.) Platform for Recombinant Protein Expression & Production
• Baculovirus Insect Cell Platform for Recombinant Protein Expression & Production
• Protein and Antibody Purification Platform
• Rabbit Monoclonal Antibody Development Platform
• Mouse Monoclonal Antibody Development Platform

Reliable, Speedy, High Quality, Cost-effective One-Stop Biology Services

• Demonstrated to be the m ost reliable partner with close to 100% success rate.
• Unmatched speed of protein and antibody production is in the industry.
• Our quality of services have won praises from top pharmaceutical and biotech customers
• 40-80% of cost saving for services.

Affordable Premium Quality Reagents

We intend to produce bulk quantity of human proteins for every known human gene as long as it has potential research application, and develop high affinity antibodies for all proteins we produce. Our premium quality reagents are provided at significant cost-saving to our customers worldwide.

• High purity recombinant proteins, majority produced in mammalian cells
• High affinity antibodies: both rabbit and mouse monoclonal antibodies
• Majority antibodies developed with protein-based antigen
• Highly sensitive and specific ELISA kits

Tags: Recombinant Protein | Antibody | ELISA kits | Influenza reagents | Transfection reagents

Hits: 48 | Read more...

What are SNPs?

How can SNPs be used as risk factors in disease development?

Human Genome Project SNP mapping goals

What is the SNP consortium?

Who are members of the SNP consortium?

Why should private companies fund a publicly accessible genome map?

Whose DNA was analyzed to create the consortium's SNP map?

Are SNP data available to the public?

Tags: Genetics

Hits: 664 | Read more...

It's really difficult to keep human embryonic stem cells (hESCs) at undifferential status for long. Fortunately, we have moved forward at rat bone mesenchymal stem cell research, and I submit the abstract to a meetig.

Adipogenic Differentiation from Mesenchymal Stem Cell (MSCs) Involves PTHrP and PPAR-γ Pathways

Abstract

Background: The potential use of cell-based therapy is one of the most exciting advances in the field of translational medicine to treat various pathological conditions that have been untreatable up to now. Chronic lung disease is rapidly becoming the primary cause of death in the US. Currently, there is no intervention that can either arrest or cure evolving or established chronic lung diseases. Knowledge of the intrinsic molecular mechanisms that allow for resistance to inflammation and recruitment of stem cells for repair would allow for the engineering of such cells for effective treatment. MSCs are bone marrow non-haematopoietic stem cells that are multipotent and can differentiate into bone, cartilage and connective tissues. Moreover MSCs present many advantages as facilities to culture or to transform genetically. We have discovered that Parathyroid Hormone-related Protein (PTHrP) and PPAR-r drive the key homeostatic lung epithelial-mesenchymal interactions, resulting in the differentiation of alveolar interstitial lipofibroblasts that are essential for normal lung development and its repair following injury. In this paper, we try to isolate CD45 (-) CD73 (+) CD90 (+) MSCs from 6 weeks old rats and further induce such cells into adipogenic cells. Meanwhile, we try to confirm our hypothesis that PTHrP and PPAR-γ related pathways are involved in the MSCs differential procedure.

Methods: Femurs and tibias were aseptically harvested from 6 weeks old Wistar rats. Whole bone marrow plugs were obtained by flushing the bone marrow cavity with an 18-gauge needle set with a syringe filled with α-MEM medium. Second passage of adherent MSCs were

Tags: Cellular Biology

Hits: 481 | Read more...